(Q38250318)

English

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials

scientific article published on 28 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

0 references

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

rheumatoid arthritis

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Sang-Cheol Bae

2

0 references

author name string

Gwan Gyu Song

1

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

Young Ho Lee

3

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

publication date

28 August 2014

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

The Korean journal of internal medicine

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

29

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

656-663

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

1 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

The pathogenesis of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Janus kinases in immune cell signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Meta-analysis: principles and procedures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Rheumatoid arthritis. Pathophysiology and implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

6 September 2017

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

31 August 2018

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164730

31 August 2018

FDA approves tofacitinib for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genome scan meta-analysis of rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25228842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3904/KJIM.2014.29.5.656

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38250318&oldid=1860665213"